2625 Townsgate Road
Suite 230
Westlake Village, CA 91361
United States
805 267 9889
https://www.genelux.com
Secteur(s): Healthcare
Secteur d’activité: Biotechnology
Employés à temps plein: 23
Nom | Titre | Payer | Exercé | Année de naissance |
---|---|---|---|---|
Mr. Thomas Zindrick J.D. | Chairman, CEO & President | 570,99k | S.O. | 1960 |
Ms. Lourie S. Zak | Chief Financial Officer | 346,19k | S.O. | 1964 |
Ms. Caroline Jewett | VP & Head of Quality | 269,26k | S.O. | 1965 |
Dr. Joseph Cappello Ph.D. | Chief Technical Officer | 213,08k | S.O. | 1957 |
Mr. Sean Ryder J.D. | General Counsel & Corporate Secretary | 380k | S.O. | 1970 |
Dr. Yong Yu Ph.D. | Senior Vice President of Clinical Development | 242,62k | S.O. | 1972 |
Prof. Paul Scigalla M.D., Ph.D. | Chief Medical Officer | S.O. | S.O. | 1946 |
Mr. Ralph Smalling B.Sc. | VP & Head of Regulatory Affairs | S.O. | S.O. | 1957 |
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer. The company is also developing V2ACT Immunotherapy for treating pancreatic cancer. Genelux Corporation has a licensing agreement with ELIAS Animal Health, LLC for V-VET1, a clinical stage animal health product candidate. The company was incorporated in 2001 and is headquartered in Westlake Village, California.
L’ISS Governance QualityScore de Genelux Corporation en date du 1 mai 2024 est 8. Les scores principaux sont Audit : 8; Société : 6; Droits des actionnaires : 8; Compensation : 9.